Lexaria Bioscience Corp. (LEXX)
11.66
+1.12
(+10.58%)
USD |
NASDAQ |
Aug 25, 16:00
11.66
0.00 (0.00%)
After-Hours: 16:23
Lexaria Bioscience Debt to Equity Ratio : 0.0183 for May 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| May 31, 2026 | 0.0183 |
| February 28, 2026 | 0.0143 |
| November 30, 2025 | 0.0207 |
| August 31, 2025 | 0.0366 |
| May 31, 2025 | 0.021 |
| February 28, 2025 | 0.0173 |
| November 30, 2024 | 0.0134 |
| August 31, 2024 | 0.0171 |
| May 31, 2024 | 0.0141 |
| February 29, 2024 | 0.0228 |
| November 30, 2023 | 0.0414 |
| May 31, 2023 | 0.0398 |
| February 28, 2023 | 0.0059 |
| November 30, 2022 | 0.0063 |
| August 31, 2022 | 0.0063 |
| May 31, 2022 | 0.0074 |
| February 28, 2022 | 0.0068 |
| November 30, 2021 | 0.0075 |
| August 31, 2021 | 0.0073 |
| May 31, 2021 | 0.0103 |
| February 28, 2021 | 0.0098 |
| November 30, 2020 | 0.0785 |
| August 31, 2020 | 0.0618 |
| May 31, 2020 | 0.009 |
| February 29, 2020 | 0.00 |
| Date | Value |
|---|---|
| November 30, 2019 | 0.00 |
| August 31, 2019 | 0.00 |
| May 31, 2019 | 0.00 |
| February 28, 2019 | 0.00 |
| November 30, 2018 | 0.00 |
| August 31, 2018 | 0.0033 |
| May 31, 2018 | 0.0035 |
| February 28, 2018 | 0.002 |
| November 30, 2017 | 0.0104 |
| August 31, 2017 | 0.0142 |
| May 31, 2017 | 0.016 |
| February 28, 2017 | 0.474 |
| November 30, 2016 | 0.5188 |
| August 31, 2016 | 1.415 |
| May 31, 2016 | 0.3728 |
| February 29, 2016 | 0.00 |
| November 30, 2015 | 0.00 |
| August 31, 2015 | 0.00 |
| May 31, 2015 | 0.0016 |
| February 28, 2015 | 0.00 |
| November 30, 2014 | 0.00 |
| July 31, 2014 | 0.227 |
| April 30, 2014 | 0.2437 |
| January 31, 2014 | 0.6341 |
| October 31, 2013 | 0.6085 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Target Group, Inc. (Canada) | -1.291 |
| InMed Pharmaceuticals, Inc. | 0.061 |
| NervGen Pharma Corp. | 0.00 |
| Milestone Pharmaceuticals, Inc. | 7.785 |
| Clearmind Medicine, Inc. | 0.0075 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 4.781M |
| Total Liabilities (Quarterly) | 0.4371M |
| Shareholders Equity (Quarterly) | 4.738M |
| Current Ratio | 10.60 |
| Net Debt Paydown Yield | 0.05% |